Research programme: lysergic acid diethylamide derivatives - Enveric Biosciences
Alternative Names: LSD derivatives - Enveric BiosciencesLatest Information Update: 26 Oct 2021
At a glance
- Originator MagicMed Industries
- Developer Enveric Biosciences
- Class Analgesics; Antidementias; Antidepressants; Antipsychotics; Anxiolytics; Ergolines; Ergot alkaloids; Neuropsychotherapeutics; Small molecules
- Mechanism of Action Serotonin 5-HT2A receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Mental disorders; Neurological disorders; Psychotic disorders
Most Recent Events
- 17 Jun 2021 Enveric Biosciences enters into definitive agreement to acquire MagicMed Industries
- 24 May 2021 Lysergic acid diethylamide derivative - MagicMed Industries is available for licensing as of 09 Jun 2021. https://www.magicmedindustries.com/about-us/
- 08 Apr 2021 MagicMed Industries enters a partnership agreement with Cognistx to develop PsyAI™